| SEGMENTS |
SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations
through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
|
|
|
|
|
|
|
|
|
|
For the three months ended March 31, |
(In thousands) |
2020 |
|
2019 |
Revenue from services: |
|
|
|
Pharmaceutical |
$ |
— |
|
|
$ |
— |
|
Diagnostics |
170,839 |
|
|
178,891 |
|
Corporate |
— |
|
|
— |
|
|
$ |
170,839 |
|
|
$ |
178,891 |
|
Revenue from products: |
|
|
|
Pharmaceutical |
$ |
31,074 |
|
|
$ |
25,301 |
|
Diagnostics |
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
$ |
31,074 |
|
|
$ |
25,301 |
|
Revenue from transfer of intellectual property and other: |
|
|
|
Pharmaceutical |
$ |
9,553 |
|
|
$ |
18,259 |
|
Diagnostics |
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
$ |
9,553 |
|
|
$ |
18,259 |
|
Operating loss: |
|
|
|
Pharmaceutical |
$ |
(14,126 |
) |
|
$ |
(29,477 |
) |
Diagnostics |
(18,133 |
) |
|
(33,569 |
) |
Corporate |
(8,503 |
) |
|
(12,272 |
) |
|
$ |
(40,762 |
) |
|
$ |
(75,318 |
) |
Depreciation and amortization: |
|
|
|
Pharmaceutical |
$ |
7,121 |
|
|
$ |
7,526 |
|
Diagnostics |
14,871 |
|
|
16,271 |
|
Corporate |
60 |
|
|
19 |
|
|
$ |
22,052 |
|
|
$ |
23,816 |
|
Loss from investment in investees: |
|
|
|
Pharmaceutical |
$ |
(134 |
) |
|
$ |
(1,854 |
) |
Diagnostics |
— |
|
|
— |
|
Corporate |
— |
|
|
— |
|
|
$ |
(134 |
) |
|
$ |
(1,854 |
) |
Revenues: |
|
|
|
United States |
$ |
180,872 |
|
|
$ |
184,894 |
|
Ireland |
11,901 |
|
|
20,534 |
|
Chile |
10,850 |
|
|
7,865 |
|
Spain |
4,156 |
|
|
4,418 |
|
Israel |
1,707 |
|
|
3,116 |
|
Mexico |
1,841 |
|
|
1,531 |
|
Other |
139 |
|
|
93 |
|
|
$ |
211,466 |
|
|
$ |
222,451 |
|
|
|
|
|
|
|
|
|
|
(In thousands) |
March 31,
2020 |
|
December 31,
2019 |
Assets: |
|
|
|
Pharmaceutical |
$ |
1,157,430 |
|
|
$ |
1,174,639 |
|
Diagnostics |
1,026,880 |
|
|
1,035,112 |
|
Corporate |
48,232 |
|
|
99,521 |
|
|
$ |
2,232,542 |
|
|
$ |
2,309,272 |
|
Goodwill: |
|
|
|
Pharmaceutical |
$ |
234,773 |
|
|
$ |
237,131 |
|
Diagnostics |
434,809 |
|
|
434,809 |
|
Corporate |
— |
|
|
— |
|
|
$ |
669,582 |
|
|
$ |
671,940 |
|
No customer represented more than 10% of our total consolidated revenue during the three months ended March 31, 2020 and 2019. As of March 31, 2020 and December 31, 2019, no customer represented more than 10% of our accounts receivable balance.
|